ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells

Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage

(2016) Ansar Karimian et al.   DNA REPAIR

Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation

(2016) Min-Jung Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents

(2016) Jaeki Min et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase

(2016) Sébastien L. Degorce et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure of the intact ATM/Tel1 kinase

(2016) Xuejuan Wang et al.   Nature Communications

The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy

(2015) Michael Goldstein et al.   Annual Review of Medicine

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

(2015) M. Kwok et al.   BLOOD

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma

(2015) Gry Irene Magnussen et al.   BMC CANCER

NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells

(2015) Zhiyun Yu et al.   CANCER LETTERS

PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells

(2015) Jiezhong Chen et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma

(2015) J. L. Pokorny et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways

(2015) M. A. Morgan et al.   CLINICAL CANCER RESEARCH

Embracing synthetic lethality of novel anticancer therapies

(2015) Ahmed Kamal et al.   Expert Opinion on Drug Discovery

Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway

(2015) Marwan Kwok et al.   LANCET

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

(2015) C. King et al.   MOLECULAR CANCER THERAPEUTICS

Development of an Expedient Process for the Multi-Kilogram Synthesis of Chk1 Inhibitor GDC-0425

(2015) Andreas Stumpf et al.   ORGANIC PROCESS RESEARCH & DEVELOPMENT

ATM and ATR as therapeutic targets in cancer

(2015) Anika Maria Weber et al.   PHARMACOLOGY & THERAPEUTICS

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736

(2015) Valentina Restelli et al.   Oncotarget

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

(2015) Fiona K. Middleton et al.   Oncotarget

Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells

(2015) Joyce P.Y. Mak et al.   Oncotarget

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

(2015) Frank P. Vendetti et al.   Oncotarget

Mammary Stem Cells and Tumor-Initiating Cells Are More Resistant to Apoptosis and Exhibit Increased DNA Repair Activity in Response to DNA Damage

(2015) Chi-Hsuan Chang et al.   Stem Cell Reports

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

(2015) Rosaria Chilà et al.   Oncotarget

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

(2015) Amy B. Hall et al.   Oncotarget

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

(2015) Bipasha Mukherjee et al.   NEOPLASIA

Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition

(2015) Venkatasubbaiah A. Venkatesha et al.   NEOPLASIA

The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells

(2014) Feng-Ze Wang et al.   APOPTOSIS

Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma

(2014) F. Al-Ejeh et al.   CLINICAL CANCER RESEARCH

Selective Targeting of the G2/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy

(2014) M.T. Dillon et al.   CLINICAL ONCOLOGY

Chemical approaches to targeting drug resistance in cancer stem cells

(2014) Panagiota A. Sotiropoulou et al.   DRUG DISCOVERY TODAY

The development of ataxia telangiectasia mutated kinase inhibitors

(2014) Martin Andrs et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells

(2014) Christopher Bryant et al.   Molecular Cancer

Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase

(2014) Ross Carruthers et al.   Molecular Oncology

Expression and Regulation of Prostate Apoptosis Response-4 (Par-4) in Human Glioma Stem Cells in Drug-Induced Apoptosis

(2014) Jayashree C. Jagtap et al.   PLoS One

CHK2 kinase in the DNA damage response and beyond

(2014) L. Zannini et al.   Journal of Molecular Cell Biology

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo

(2014) M Signore et al.   Cell Death & Disease

Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors

(2014) Paul A Barsanti et al.   ACS Medicinal Chemistry Letters

Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors

(2014) Paul A Barsanti et al.   ACS Medicinal Chemistry Letters

Pyrimidine-Based Tricyclic Molecules as Potent and Orally Efficacious Inhibitors of Wee1 Kinase

(2014) Yunsong Tong et al.   ACS Medicinal Chemistry Letters

NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro

(2013) Wen-juan Wang et al.   ACTA PHARMACOLOGICA SINICA

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

(2013) Ryan Montano et al.   BMC CANCER

UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines

(2013) Guoyi Wu et al.   BMC CANCER

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

(2013) Q. Liu et al.   CANCER RESEARCH

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

(2013) C. J. Huntoon et al.   CANCER RESEARCH

Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

(2013) C. G. Engelke et al.   CLINICAL CANCER RESEARCH

Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

(2013) Carlos Rodrigo Gil del Alcazar et al.   CLINICAL CANCER RESEARCH

Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

(2013) Thomas P Matthews et al.   Expert Opinion on Drug Discovery

Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019

(2013) Donatella Vecchio et al.   INTERNATIONAL JOURNAL OF CANCER

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

(2013) Constance King et al.   INVESTIGATIONAL NEW DRUGS

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine

(2013) Hong-Quan Duong et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

(2013) Kevin M. Foote et al.   JOURNAL OF MEDICINAL CHEMISTRY

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

(2013) M. A. Batey et al.   MOLECULAR CANCER THERAPEUTICS

The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

(2013) Y. Dai et al.   MOLECULAR CANCER THERAPEUTICS

Activation of the phosphorylation of ATM contributes to radioresistance of glioma stem cells

(2013) WEI ZHOU et al.   ONCOLOGY REPORTS

Targeting Head and Neck Cancer Stem Cells to Overcome Resistance to Photon and Carbon Ion Radiation

(2013) Gérald Bertrand et al.   Stem Cell Reviews and Reports

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest

(2013) L Lundholm et al.   Cell Death & Disease

Two Distinct Modes of ATR Activation Orchestrated by Rad17 and Nbs1

(2013) Bunsyo Shiotani et al.   Cell Reports

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line

(2013) Douglas D. Fang et al.   Frontiers of Medicine

Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors

(2012) Rahman Shah Zaib Saleem et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Characterization of Glioma Stem Cells Through Multiple Stem Cell Markers and Their Specific Sensitization to Double-Strand Break-Inducing Agents by Pharmacological Inhibition of Ataxia Telangiectasia Mutated Protein

(2012) Alessandro Raso et al.   BRAIN PATHOLOGY

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition

(2012) I M Pires et al.   BRITISH JOURNAL OF CANCER

Evaluation of checkpoint kinase targeting therapy in Acute Myeloid Leukemia with complex karyotype

(2012) Christine Didier et al.   CANCER BIOLOGY & THERAPY

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

(2012) Remko Prevo et al.   CANCER BIOLOGY & THERAPY

Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma

(2012) M. R. Russell et al.   CANCER RESEARCH

Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family

(2012) L. M. Pouliot et al.   CANCER RESEARCH

Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control

(2012) Sarah E. Golding et al.   CELL CYCLE

Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo

(2012) Laura Carrassa et al.   CELL CYCLE

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

(2012) M. I. Walton et al.   CLINICAL CANCER RESEARCH

Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

(2012) Michael Lainchbury et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Checkpoint Kinase Inhibitor (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas

(2012) Vibha Oza et al.   JOURNAL OF MEDICINAL CHEMISTRY

DNA Damage Repair Pathways in Cancer Stem Cells

(2012) M. Maugeri-Sacca et al.   MOLECULAR CANCER THERAPEUTICS

WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas

(2012) V. Caretti et al.   MOLECULAR CANCER THERAPEUTICS

Exploring Protein Kinase Inhibitors

(2012) Yeon Jeong Kim et al.   PANCREAS

Breast Cancer Stem Cell-Like Cells Are More Sensitive to Ionizing Radiation than Non-Stem Cells: Role of ATM

(2012) Seog-Young Kim et al.   PLoS One

Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery

(2012) S. Karve et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human Embryonic Stem Cells Fail to Activate CHK1 and Commit to Apoptosis in Response to DNA Replication Stress

(2012) Joëlle A. Desmarais et al.   STEM CELLS

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

(2012) E Fokas et al.   Cell Death & Disease

Radioprotection by Hymenialdisine-Derived Checkpoint Kinase 2 Inhibitors

(2011) Thu N. T. Nguyen et al.   ACS Chemical Biology

WEE1 inhibition sensitizes osteosarcoma to radiotherapy

(2011) Jantine PosthumaDeBoer et al.   BMC CANCER

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

(2011) A Peasland et al.   BRITISH JOURNAL OF CANCER

CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors

(2011) Victoria E. Anderson et al.   CANCER RESEARCH

Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: Implications for drug resistance and in vitro drug screening models

(2011) Michal Sabisz et al.   CELL CYCLE

Unleashing Chk1 in cancer therapy

(2011) Laura Carrassa et al.   CELL CYCLE

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

(2011) M Bartucci et al.   CELL DEATH AND DIFFERENTIATION

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells

(2011) K. A. Bridges et al.   CLINICAL CANCER RESEARCH

Current Inhibitors of Checkpoint Kinase 2

(2011) T. N.T. Nguyen et al.   CURRENT MEDICINAL CHEMISTRY

CGK733 does not inhibit ATM or ATR kinase activity in H460 human lung cancer cells

(2011) Serah Choi et al.   DNA REPAIR

Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration

(2011) Da-Qing Yang et al.   DRUG DISCOVERY TODAY

Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer

(2011) Qingsong Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

(2011) Jean-Damien Charrier et al.   JOURNAL OF MEDICINAL CHEMISTRY

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

(2011) J. M. Kreahling et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines

(2011) B. Sarcar et al.   MOLECULAR CANCER THERAPEUTICS

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structure-Specific DNA Endonuclease Mus81/Eme1 Generates DNA Damage Caused by Chk1 Inactivation

(2011) Josep V. Forment et al.   PLoS One

Inhibition of Ataxia Telangiectasia- and Rad3 -Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor-Initiating Cell Fraction

(2011) Eike Gallmeier et al.   STEM CELLS

Anticancer therapy with checkpoint inhibitors: what, where and when?

(2011) Michelle D. Garrett et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints

(2010) Yungan Tao et al.   CELL CYCLE

Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2

(2010) John J. Caldwell et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

(2010) M. I. Walton et al.   MOLECULAR CANCER THERAPEUTICS

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2

(2009) Stephen Hilton et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding

(2009) Kyle A. Emmitte et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

(2009) Lyndsay M. Murrow et al.   BREAST CANCER RESEARCH AND TREATMENT

Common mechanisms of PIKK regulation

(2009) Courtney A. Lovejoy et al.   DNA REPAIR

A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe

(2009) Oliver Riesterer et al.   INVESTIGATIONAL NEW DRUGS

Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid  -amide]

(2009) A. G. Jobson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

(2009) L. A. Parsels et al.   MOLECULAR CANCER THERAPEUTICS

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

(2009) S. E. Golding et al.   MOLECULAR CANCER THERAPEUTICS

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response

(2009) H. Nishida et al.   NUCLEIC ACIDS RESEARCH

Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

(2009) Elizabeth Iorns et al.   PLoS One

Atomic resolution structure of the cytoplasmic domain ofYersinia pestisYscU, a regulatory switch involved in type III secretion

(2009) George T. Lountos et al.   PROTEIN SCIENCE

The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation

(2009) John P Alao et al.   Radiation Oncology

Transient Inhibition of ATM Kinase Is Sufficient to Enhance Cellular Sensitivity to Ionizing Radiation

(2008) M. D. Rainey et al.   CANCER RESEARCH

Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase η-deficient human cells treated with cisplatin and oxaliplatin

(2008) Séverine Cruet-Hennequart et al.   DNA REPAIR

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

(2008) A. Dubrovska et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting phosphoinositide 3-kinase—Moving towards therapy

(2007) Romina Marone et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Synthesis and structure–activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases

(2007) Jeff B. Smaill et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY